Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles”In the company’s words, NCT01222286 on ClinicalTrials.gov
- Tested for
- Smoldering Multiple Myeloma
- Main trialPhase 2
- “The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.”In the company’s words, NCT01222286 on ClinicalTrials.gov
Other drugs for Smoldering Multiple Myeloma
- LinvoseltamabRegeneron · Phase 3
- DaratumumabJohnson & Johnson (Janssen) · Phase 1
- JNJ-102299639Johnson & Johnson (Janssen) · Phase 1
- RamantamigJohnson & Johnson (Janssen) · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | Jul 2012 | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026